Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
PLx Pharma Inc is a drug manufacturers-specialty & generic business based in the US. PLx Pharma shares (PLXP) are listed on the NASDAQ and all prices are listed in US Dollars. PLx Pharma employs 8 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$2.36 - $11.15|
|50-day moving average||$9.14|
|200-day moving average||$6.31|
|Wall St. target price||$16.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.87|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$30,430|
|Return on assets TTM||-37.29%|
|Return on equity TTM||-191.61%|
|Market capitalisation||$242.4 million|
TTM: trailing 12 months
There are currently 805,984 PLx Pharma shares held short by investors – that's known as PLx Pharma's "short interest". This figure is 8.8% up from 740,481 last month.
There are a few different ways that this level of interest in shorting PLx Pharma shares can be evaluated.
PLx Pharma's "short interest ratio" (SIR) is the quantity of PLx Pharma shares currently shorted divided by the average quantity of PLx Pharma shares traded daily (recently around 629675). PLx Pharma's SIR currently stands at 1.28. In other words for every 100,000 PLx Pharma shares traded daily on the market, roughly 1280 shares are currently held short.
However PLx Pharma's short interest can also be evaluated against the total number of PLx Pharma shares, or, against the total number of tradable PLx Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PLx Pharma's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 PLx Pharma shares in existence, roughly 40 shares are currently held short) or 0.0381% of the tradable shares (for every 100,000 tradable PLx Pharma shares, roughly 38 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against PLx Pharma.
Find out more about how you can short PLx Pharma stock.
We're not expecting PLx Pharma to pay a dividend over the next 12 months.
PLx Pharma's shares were split on a 1:8 basis on 19 April 2017. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your PLx Pharma shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for PLx Pharma shares which in turn could have impacted PLx Pharma's share price.
Over the last 12 months, PLx Pharma's shares have ranged in value from as little as $2.36 up to $11.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PLx Pharma's is 5.1526. This would suggest that PLx Pharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.
PLx Pharma Inc. , a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system, which provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable, and predictable platelet inhibition as compared to enteric-coated aspirin, as well as reduces the risk of stomach erosions and ulcers as compared with immediate-release aspirin, after seven days of treatment. Its product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard drug delivery system, such as PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen 400 mg, which are in Phase I clinical stage for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. PLx Pharma Inc. was founded in 2002 and is headquartered in Sparta, New Jersey. .
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.